The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

Importantly, the medication is not an opioid, which means that medical professionals now have an alternative to treating acute pain that doesn’t require using a potentially addictive analgesic.

The FDA's sign-off on the medication comes as the agency says it is prioritizing supporting the development of non-opioid pain treatment. Suzetrigine is the first non-opioid analgesic – or ...

There is a considerable need for novel analgesics that are more effective or safer than existing drugs. Richard Silverman highlights some of the research that led to the discovery of a novel ...

Am J Health Syst Pharm. 2007;64(11):1148-1152. Health care organizations around the nation have been working to reduce the use of meperidine as a first-line agent for pain management. Despite the ...

VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved on December 12, 2024. (active ...

All three categories of drugs were better than placebo with at ... comparison of the safety and efficacy of the available analgesics to inform clinical guidelines and practice," the group examined ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

Additionally, the development of combination drugs that incorporate multiple analgesics into a single dose has enhanced pain ...